Skip to main content
TipRanks
Go Ultimate75% OFF

ZyVersa Therapeutics (ZVSA) AI Stock Analysis

206 Followers
ZVSA

ZyVersa Therapeutics

(Other OTC:ZVSA)

Select Model
Rating:38Underperform
Price Target:$0.05â–²(4400.00% Upside)
Action:reiterated
Date:10/15/26

Primarily driven by poor financial performance including negative equity and cash burn, along with unfavorable valuation and the adverse corporate event of moving to OTC Pink; technical oversold signals provide minor offset but do not alter the high-risk profile.

Positive Factors
Therapeutic FocusA focused presence in renal and inflammatory disease gives ZyVersa a defined therapeutic direction and concentrates resources on conditions where new treatments may address substantial medical needs. This focus can support clearer development priorities over the next several quarters.
Negative Factors
No RevenueZero revenue across multiple years confirms that ZyVersa remains pre-commercial and has no demonstrated sales base to fund operations. Until a candidate reaches approval and commercialization, the business must rely on financing or other capital sources to sustain development.

ZyVersa Therapeutics (ZVSA) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%100%ZVSA-67.86%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$810
Dividend Yield
―
Average Volume (3M)
14.38K
Price to Earnings (P/E)
0.0
Beta (1Y)
1.05
Revenue Growth
―
EPS Growth
57.26%
Country
US
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ZyVersa Therapeutics Business Overview & Revenue Model

Company Description

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a chole...

ZyVersa Therapeutics Financial Statement Overview

Summary

Extremely weak financials with no revenue, negative stockholders' equity, and persistent negative cash flows highlighting high insolvency and funding risks.

Income Statement

15Very Negative

Balance Sheet

10Very Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Dec 2021
Income Statement
Total Revenue000000
Gross Profit00-6,933-10.40K-10.40K-10.40K
EBITDA-24.69M-25.29M-9.14B-107.74M-14.43M-7.25M
Net Income-24.49M-24.95M-9.41B-98.30M-14.05M-8.08M
Balance Sheet
Total Assets742.22M347.90M20.60M22.11M118.51M1.13M
Cash, Cash Equivalents and Short-Term Investments302.66M101.78M1.53M3.14M5.90M328.58K
Total Debt1.20B008,656108.76K9.15M
Total Liabilities14.87B12.73B12.08M11.04M18.51M13.63M
Stockholders Equity-14.12M-12.39B8.52M11.07M99.99M-12.50M
Cash Flow
Free Cash Flow-2.62B-5.11M-7.56M-8.72M-1.49M-5.08M
Operating Cash Flow-2.62B-5.11M-7.56M-8.72M-4.89M-5.08M
Investing Cash Flow000000
Financing Cash Flow2.83B3.69M5.95M5.96M1.87M5.23M

ZyVersa Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.00

Price Trends

50DMA0.09Negative
100DMA0.12Negative
200DMA0.16Negative

Market Momentum

MACD-0.01Positive
RSI23.25Positive
STOCH8.50Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVSA, the sentiment is Negative. The current price of 0.00 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 23.25 is Positive, neither overbought nor oversold. The STOCH value of 8.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZVSA.

ZyVersa Therapeutics Risk Analysis

ZyVersa Therapeutics disclosed 86 risk factors in its most recent earnings report. ZyVersa Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Following a reverse stock split, the resulting market price of our Common Stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our Common Stock may not improve.Q4, 2023
2.Our reverse stock split may decrease the liquidity of the shares of our Common Stock.Q4, 2023
3.Unless our Common Stock continues to be listed on a national securities exchange it will become subject to the so-called "penny stock" rules that impose restrictive sales practice requirements.Q4, 2023

ZyVersa Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ZVSA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SCNISCNI41Neutral$534.52K-0.54-23.86%―143.06%94.98%
ZVSAZVSA38Underperform$8100.000.79%――57.26%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%ZVSASCNIADTXCEROPBMCDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ZVSA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ZVSAZyversa Therapeutics, Inc.0.04-0.10-69.39%
SCNIScinai Immunotherapeutics Ltd. Sponsored Adr1.58-34.20-95.58%
ADTXAditxt, Inc.0.04-771.08-99.99%
CEROCero Therapeutics Holdings, Inc.0.01-0.06-85.07%
PBMPsyence Biomedical Ltd.2.97-6.47-68.53%
CDTCdt Equity Inc.0.23-218749.77-100.00%

ZyVersa Therapeutics Corporate Events

Delistings and Listing Changes

ZyVersa Therapeutics Transitions to OTC Pink Market

Negative
Jul 17, 2026

Effective July 16, 2026, ZyVersa Therapeutics, Inc. ceased trading on the OTCQB Venture Market and began trading on the OTC Pink Limited Market. The move to the OTC Pink tier represents a change in the company’s trading status that may affect investo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 15, 2026